Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

 Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

Shots:

  • Novartis acquires AveXis, in all stock transaction with its AVXS-101 candidate for replacing the defective SMN1 gene. AveXis to receive $218/share making total deal value $8.7B
  • The focus of the agreement is to utilize AveXis’ AAV9 gene therapy platform to develop therapies for multiple therapeutic areas
  • AVXS-101 is a gene replacement therapy candidate targeted for spinal muscular atrophy (SMA) Type 1 and has received FDA’s ODD and Breakthrough Therapy Designation for SMA & SMA Type 1

Click here to read full press release/ article | Ref: Novartis | Image:  Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post